Citadel Advisors’s Novavax NVAX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$9.15M Buy
1,123,746
+50,019
+5% +$453K ﹤0.01% 3379
2025
Q4
$7.22M Sell
1,073,727
-212,145
-16% -$1.6M ﹤0.01% 3713
2025
Q3
$11.1M Buy
1,285,872
+456,628
+55% +$3.55M ﹤0.01% 3116
2025
Q2
$5.22M Sell
829,244
-838,473
-50% -$5.55M ﹤0.01% 4043
2025
Q1
$10.7M Buy
1,667,717
+814,226
+95% +$6.73M ﹤0.01% 2771
2024
Q4
$6.86M Buy
853,491
+289,446
+51% +$2.79M ﹤0.01% 3475
2024
Q3
$7.12M Sell
564,045
-58,915
-9% -$761K ﹤0.01% 3405
2024
Q2
$7.89M Buy
622,960
+332,309
+114% +$3.34M ﹤0.01% 3088
2024
Q1
$1.39M Buy
+290,651
New +$1.35M ﹤0.01% 6246
2023
Q4
Sell
-10,970
Closed -$67.2K 14930
2023
Q3
$79.4K Sell
10,970
-74,215
-87% -$593K ﹤0.01% 11191
2023
Q2
$633K Buy
85,185
+84,091
+7,687% +$661K ﹤0.01% 7424
2023
Q1
$7.58K Sell
1,094
-368,053
-100% -$3.39M ﹤0.01% 13709
2022
Q4
$3.79M Sell
369,147
-671,146
-65% -$11.8M ﹤0.01% 4338
2022
Q3
$18.9M Buy
1,040,293
+351,134
+51% +$15.2M ﹤0.01% 1931
2022
Q2
$35.4M Buy
689,159
+124,043
+22% +$6.43M 0.01% 1309
2022
Q1
$41.6M Buy
565,116
+484,628
+602% +$43.2M 0.01% 1250
2021
Q4
$11.5M Sell
80,488
-111,244
-58% -$19.1M ﹤0.01% 2831
2021
Q3
$39.7M Sell
191,732
-491,736
-72% -$108M 0.01% 1308
2021
Q2
$145M Buy
683,468
+326,732
+92% +$59.9M 0.03% 480
2021
Q1
$64.7M Sell
356,736
-356,459
-50% -$71M 0.02% 841
2020
Q4
$79.5M Buy
713,195
+389,536
+120% +$41.4M 0.02% 671
2020
Q3
$35.1M Sell
323,659
-456,749
-59% -$55.6M 0.01% 1103
2020
Q2
$65M Buy
780,408
+751,875
+2,635% +$28.8M 0.02% 634
2020
Q1
$387K Buy
+28,533
New +$241K ﹤0.01% 6882
2019
Q4
Sell
-24,315
Closed -$105K 9537
2019
Q3
$122K Buy
+24,315
New +$133K ﹤0.01% 8392
2019
Q2
Sell
-280,362
Closed -$2.21M 9641
2019
Q1
$3.09M Buy
280,362
+218,601
+354% +$6.9M ﹤0.01% 3705
2018
Q4
$2.27M Buy
61,761
+40,055
+185% +$1.55M ﹤0.01% 3946
2018
Q3
$817K Buy
21,706
+2,917
+16% +$82.1K ﹤0.01% 5885
2018
Q2
$504K Buy
18,789
+11,089
+144% +$375K ﹤0.01% 6356
2018
Q1
$323K Sell
7,700
-64,225
-89% -$2.58M ﹤0.01% 6629
2017
Q4
$1.78M Buy
71,925
+66,267
+1,171% +$1.62M ﹤0.01% 3792
2017
Q3
$129K Sell
5,658
-12,259
-68% -$274K ﹤0.01% 6938
2017
Q2
$412K Buy
17,917
+13,638
+319% +$268K ﹤0.01% 5404
2017
Q1
$109K Buy
4,279
+2,820
+193% +$77.5K ﹤0.01% 6825
2016
Q4
$37K Sell
1,459
-27,448
-95% -$801K ﹤0.01% 6935
2016
Q3
$1.2M Buy
28,907
+26,954
+1,380% +$3.48M ﹤0.01% 3590
2016
Q2
$284K Buy
1,953
+128
+7% +$14.7K ﹤0.01% 5297
2016
Q1
$188K Sell
1,825
-113,244
-98% -$12.1M ﹤0.01% 5683
2015
Q4
$19.3M Buy
115,069
+82,962
+258% +$12.8M 0.02% 862
2015
Q3
$4.54M Buy
32,107
+10,460
+48% +$2.35M ﹤0.01% 2042
2015
Q2
$4.82M Buy
21,647
+16,492
+320% +$2.9M ﹤0.01% 2101
2015
Q1
$853K Buy
5,155
+2,301
+81% +$374K ﹤0.01% 4142
2014
Q4
$338K Sell
2,854
-1
-0% -$105 ﹤0.01% 5254
2014
Q3
$238K Buy
2,855
+136
+5% +$12.3K ﹤0.01% 5536
2014
Q2
$251K Sell
2,719
-12,594
-82% -$1.11M ﹤0.01% 5295
2014
Q1
$1.39M Buy
15,313
+10,961
+252% +$1.22M ﹤0.01% 3016
2013
Q4
$445K Buy
4,352
+3,633
+505% +$257K ﹤0.01% 4159
2013
Q3
$45K Sell
719
-313
-30% -$17.6K ﹤0.01% 5845
2013
Q2
$42K Buy
+1,032
New +$44.7K ﹤0.01% 5748

Other funds holding NVAX

Citadel Advisors's NVAX Position: Q1 2026 in Review

Citadel Advisors increased its Novavax (NVAX) stake by 4.7% in Q1 2026, buying an estimated $453K and bringing the position to 1,123,746 shares worth $9.15M. The position accounts for ﹤0.01% of the portfolio, ranked #3379.

Citadel Advisors first reported a position in NVAX in Q2 2013 and has held it in 49 quarters since. The position peaked at $145M in Q2 2021. 257 funds tracked by Wall St. Rank hold NVAX as of Q1 2026.

  • Citadel Advisors held 1,123,746 shares of Novavax worth $9.15M as of Q1 2026.
  • Citadel Advisors bought 50,019 Novavax shares in Q1 2026, an estimated $453K.
  • Novavax made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #3379 holding.
  • Citadel Advisors first reported a position in Novavax in Q2 2013 and has held it in 49 quarters since.
  • Citadel Advisors's Novavax position peaked at $145M in Q2 2021.
  • 257 funds tracked by Wall St. Rank held Novavax as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.